Health News Releases

  • Today November 13
November 18, 2014 11:35
Merck Announces Global Strategic Alliance with Pfizer on Anti-PD-L1 to Accelerate Presence in Immuno-Oncology
Merck (MRK GY) (FWB:MRK) announced today that it has entered into a global agreement with Pfizer Inc. (NYSE:PFE) to co-develop and co-commercialize MSB0010718C, an investigational anti-PD-L1 antibody
November 14, 2014 16:45
Catalent Acquires Micron Technologies
Catalent, Inc. (NYSE:CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has acqui
November 13, 2014 22:00
Global Survey Finds That Pancreatic Cancer, a Leading Cause of Cancer Deaths, is Virtually Unknown by Many in Europe and US
While it may not be surprising that breast and lung cancers are top of mind when people hear the word “cancer,” 60% of respondents to a recent six-country survey about cancer awareness know almost not
November 11, 2014 14:00
Thomas Casey Named Executive Vice President, Chief Financial Officer for Acelity
Acelity L.P. Inc. announced today the appointment of Thomas Casey, a well-respected financial leader, as Executive Vice President and Chief Financial Officer. Tom brings to Acelity 30 years of fina
November 10, 2014 13:05
Takeda Announces Abstracts for ADCETRIS® (brentuximab vedotin) in Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma and Ixazomib in Multiple Myeloma to be Presented at 56th American Society of Hematology Annual Meeting
Takeda Pharmaceutical Company Limited (TSE:4502) today announced that abstracts of interest from studies on VELCADE® (bortezomib), ADCETRIS® (brentuximab vedotin) and the investigational oral proteaso
November 10, 2014 11:15
Avedro Granted Korean Approval for its KXL® Cross-Linking System for Lasik Xtra®
Avedro Inc., a Boston-based ophthalmic medical device and pharmaceutical company announces today that it has been granted approval from the South Korean Ministry of Food and Drug Safety (MFDS, formerl
November 07, 2014 19:50
New subgroup analysis shows Asian non-small cell lung cancer patients with most common EGFR mutation (del19) lived significantly longer with first-line GIOTRIF® (afatinib*) compared to chemotherapy
For Media In Asian Countries Only For Whom The Data Is Relevant (For media outside UK, US and Canada only) Boehringer Ingelheim today announced data from a pre-specified subgroup-analysis of the pi
November 06, 2014 10:00
GVK BIO Signs Definitive Agreement to Acquire Vanta Bioscience
Asia’s leading Discovery Research and Development organization, GVK BIO, announced the signing of a definitive agreement to acquire Vanta Bioscience, a full service preclinical GLP toxicology and safe
November 04, 2014 22:00
KineMed Receives Grant to Apply Novel Method for Measuring Muscle Mass in Infants and Children for the Diagnosis and Prevention of Malnutrition and Growth Stunting
KineMed, Inc. (www.kinemed.com) announced today that it has been awarded a three-year grant by the Bill & Melinda Gates Foundation to apply its novel, proprietary non-invasive measurement of skeletal
November 04, 2014 10:35
FDA Medicare study in 134,000 atrial fibrillation patients confirms positive safety profile and effectiveness of Pradaxa® in general practice
Non US, Non UK, Non Canadian Media On October 30, 2014, the U.S. Food and Drug Administration (FDA) Medicare analysis of 134,000 atrial fibrillation (AF) patients treated with either Pradaxa® (dabi
October 28, 2014 21:00
KineMed and U.S. Army Announce Collaboration to Measure Muscle Function and Response During Military Operations
KineMed, Inc. and the U.S. Army Research Institute of Environmental Medicine’s (USARIEM) Military Nutrition Division announced today they are entering into a partnership to examine KineMed’s platform
October 28, 2014 13:50
Acelity Appoints Greg Kayata Senior Vice President, Human Resources
Acelity announced today that Greg Kayata has been named Senior Vice President, Human Resources, effective immediately. Greg replaces David Lillback, who announced earlier this year he will retire in N
October 22, 2014 11:40
Boehringer Ingelheim initiates global Phase III study investigating nintedanib* in patients with colorectal cancer refractory to standard treatments
For Ex-US and Ex-UK Media Only Boehringer Ingelheim today announced the enrolment of the first patient in a new global Phase III study in patients with advanced colorectal cancer (CRC). Colorectal
October 22, 2014 10:35
Many Koreans Underestimate Stroke, Would Miss Warning Signs Despite High Global Death Rate, Prevalence among Women
Despite its being the second leading cause of death worldwide, many people still do not recognize the threat stroke poses and the warning signs associated with it, according to a new public opinion st
October 21, 2014 13:35
GVK BIO Announces Successful Completion of Drug Repurposing Efforts to Identify Novel Indications
GVK Biosciences (GVK BIO, www.gvkbio.com), Asia’s leading integrated Discovery Research and Development organization, today announced the successful completion of in-silico based alternative indicatio
October 21, 2014 13:05
Phase II Data in Crohn’s Disease for Celgene’s Oral Antisense Therapy GED-0301 to Be Presented at UEG Week 2014
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that results from a double-blind, placebo-controlled, multicenter phase II trial of GED-0301
October 20, 2014 11:05
Clinical Trial at Kyoto Medical Center Proves Efficacy of Curcumin in Knee Osteoarthritis
The Orthopedics Division at National Hospital Organization, Kyoto Medical Center, announced that it has confirmed the efficacy of Theracrumin®, absorption enhanced curcumin*1 on knee osteoarthritis, b
October 17, 2014 17:45
Boehringer Ingelheim’s OFEV™ (nintedanib*) approved by the FDA for the treatment of idiopathic pulmonary fibrosis
For media outside UK, US and Canada Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved OFEV™ (nintedanib*) for the treatment of idiopathic pulmonary fi
October 17, 2014 15:35
Xagenic Appoints Timothy I. Still as President & Chief Executive Officer
Xagenic, a molecular diagnostics company developing the first lab-free molecular diagnostic platform with a 20 minute time-to-result, today announced the appointment of Timothy I. Still as President a
October 16, 2014 20:25
REMINDER: 22nd Century Group to Ring the New York Stock Exchange Closing Bell - Today at 4pm EDT
22nd Century Group, Inc. (NYSE MKT:XXII) announced today that Joseph Pandolfino, Founder and CEO of 22nd Century Group, together with other members of senior management, will ring The Closing Bell® at
October 16, 2014 11:35
22nd Century Group to Ring the New York Stock Exchange Closing Bell
22nd Century Group, Inc. (NYSE MKT:XXII, www.xxiicentury.com/irtools) announced today that Joseph Pandolfino, Founder and CEO of 22nd Century Group, together with other members of senior management, w
October 15, 2014 11:45
Quintiles Wins Society for Clinical Research Sites’ 2014 Eagle Award
Quintiles today announced that the company was awarded the Society for Clinical Research Sites’ (SCRS) 2014 Clinical Research Organization (CRO) Eagle Award. The award, which recognizes outstanding le
Director Seo Hyo-seok delivered his “Free from Chemical Medicine” speech.
October 15, 2014 09:00
“Steroids OUT!” A Korean Medicine Doctor Banning Chemical Medicine
About 123,000 patients with atopic dermatitis, rhinitis, and asthma and 32,000 patients with pulmonary emphysema, bronchiectasis, and pulmonary fibrosis have been cured.” There is a Korean medicine
October 13, 2014 13:45
Covidien Promotes Greater Global Awareness of Thrombosis Risks
As part of a global effort to highlight the threat posed by venous thromboembolism (VTE), Covidien plc today announced it will support the inaugural World Thrombosis Day campaign as a Global Partner.
October 13, 2014 11:40
New Analyses of Oral OTEZLA® (Apremilast) Presented at EADV Show Efficacy in Difficult-to-Treat Areas of Moderate to Severe Plaque Psoriasis
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that results from additional efficacy and safety analyses of OTEZLA® (apremilast) from the E
25 per page50 per page75 per page100 per page